How is pulmonary hypertension graded based on mean pulmonary artery pressure and functional class, and what are the recommended management strategies for each grade?

Pulmonary Hypertension Grading and Management

Pulmonary hypertension is now defined as mean pulmonary artery pressure (mPAP) >20 mmHg (revised from the previous ≥25 mmHg threshold), with further hemodynamic classification based on pulmonary arterial wedge pressure (PAWP) and pulmonary vascular resistance (PVR), while functional severity is graded using WHO Functional Class (WHO-FC) I-IV, which directly guides treatment intensity. 1

Hemodynamic Classification

The hemodynamic grading distinguishes three main patterns:

• Pre-capillary PH: mPAP >20 mmHg, PAWP ≤15 mmHg, PVR >2 Wood Units
• Isolated post-capillary PH: mPAP >20 mmHg, PAWP >15 mmHg, PVR ≤2 WU
• Combined post- and pre-capillary PH: mPAP >20 mmHg, PAWP >15 mmHg, PVR >2 WU 1

The revised definition recognizing mPAP >20 mmHg (rather than ≥25 mmHg) emerged from observational data showing that patients with mPAP 21-24 mmHg have intermediate prognosis—worse than those without PH but better than conventional PH—and this "mild PH" represents approximately one-third of all PH cases 2. This lower threshold aims to identify patients earlier in the disease course, which is critical since diagnostic delays are common and linked to increased morbidity and shortened survival 3, 4.

Functional Classification (WHO-FC)

Functional severity uses WHO Functional Class grading:

• WHO-FC I: No limitation of physical activity
• WHO-FC II: Slight limitation; comfortable at rest but ordinary activity causes symptoms
• WHO-FC III: Marked limitation; comfortable at rest but less-than-ordinary activity causes symptoms
• WHO-FC IV: Unable to perform any physical activity without symptoms; signs of right heart failure present

Risk Stratification-Based Management Algorithm

For pulmonary arterial hypertension (PAH - Group 1 PH), treatment intensity is determined by risk stratification into low, intermediate, or high risk categories 5:

Initial Treatment Strategy

Low or Intermediate Risk (WHO-FC II-III):

• Initial oral combination therapy is now preferred over monotherapy, particularly ambrisentan plus tadalafil, which has proven superior to monotherapy in delaying clinical failure 5
• Alternative: Initial monotherapy may be considered in select low-risk patients

High Risk (WHO-FC IV):

• Initial combination therapy including intravenous prostacyclin analogues should be used, with IV epoprostenol prioritized since it has reduced 3-month mortality in high-risk PAH patients 5

Vasoreactivity Testing

For idiopathic, heritable, or drug-associated PAH only:

• Perform acute vasoreactivity testing during right heart catheterization
• Vasoreactive patients: Calcium channel blocker (CCB) therapy
• Non-vasoreactive patients: Proceed with combination therapy as above 5

Sequential Escalation for Inadequate Response

If inadequate clinical response to initial therapy:

1. Sequential double combination therapy targeting different pathways (endothelin, nitric oxide-cGMP, prostacyclin) 5
2. If still inadequate: Triple combination therapy 5
3. Critical caveat: Riociguat and PDE-5 inhibitors are contraindicated together 5

Advanced Interventions

Consider eligibility for lung transplantation after inadequate response to initial therapy; refer soon after inadequate response confirmed on maximal combination therapy 5:

• Lung transplantation: Class I recommendation for WHO-FC III-IV after failure of maximal medical therapy 5
• Balloon atrial septostomy (BAS): Class IIb recommendation for WHO-FC III-IV; regarded as palliative or bridging procedure in patients deteriorating despite maximal medical therapy 5

ICU Management (WHO-FC IV)

For decompensated patients with high heart rate (>110 bpm), low systolic blood pressure (<90 mmHg), low urine output, and rising lactate:

• Hospitalization in ICU: Class I recommendation 5
• Inotropic support: Class I recommendation for hypotensive patients 5

Key Clinical Pitfalls

The most common diagnostic error is delay in recognition due to nonspecific symptoms (dyspnea on exertion, fatigue). Transthoracic echocardiography serves as the key screening tool, but right heart catheterization remains mandatory for definitive diagnosis and hemodynamic characterization 6, 7.

For Group 2 PH (left heart disease) and Group 3 PH (lung disease), treatment focuses on the underlying condition rather than PAH-specific vasodilators, though inhaled treprostinil recently gained approval for Group 3 PH with interstitial lung disease 8.

The paradigm has shifted from sequential monotherapy to upfront combination therapy as standard of care, with triple therapy increasingly becoming the norm for inadequate responders 4, 8.